Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2771)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 28, 2024 (publication date) through May 10, 2025
Times Cited of This Article
- Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kong Y, Dong Q, Jin P, Li MY, Ma L, Yi QJ, Miao YE, Liu HY, Liu JG. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World J Gastroenterol 2024; 30(40): 4367-4375 [PMID: 39494102 DOI: 10.3748/wjg.v30.i40.4367] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i40/4367.htm |
| Number | Citing Articles |
| 1 |
Wen-Jia Zuo, Lin-xiao-xi Ma, Zhi-hong Wang, Xu-chen Cao, Xin-jian Jia, Wen-he Zhao, Ming-liang Zhang, Hong-wei Yang, Mao-shan Chen, Jing Wang, Xiao-yu Liu, Hao Zhang, Xiu-chun Chen, Dong Song, Hao Wang, Xiao-peng Ma, Ya-Bing Wang, Hao Yu, Zhong-Hua Wang, Zhi-Ming Shao. Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial. Cancer Letters 2025; : 217785 doi: 10.1016/j.canlet.2025.217785
|